These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 394829)

  • 1. Purified viral neuraminidase vaccine to control influenza.
    Arora DJ
    Can Med Assoc J; 1979 Dec; 121(12):1575-9. PubMed ID: 394829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing perspective on immunization against influenza.
    Johansson BE; Brett IC
    Vaccine; 2007 Apr; 25(16):3062-5. PubMed ID: 17276554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza viral neuraminidase: the forgotten antigen.
    Johansson BE; Cox MM
    Expert Rev Vaccines; 2011 Dec; 10(12):1683-95. PubMed ID: 22085172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees.
    Kilbourne ED; Cerini CP; Khan MW; Mitchell JW; Ogra PL
    J Immunol; 1987 May; 138(9):3010-3. PubMed ID: 3571981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition.
    Johansson BE; Kilbourne ED
    Virology; 1996 Nov; 225(1):136-44. PubMed ID: 8918540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
    Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
    Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of neuraminidase monospecific (HEqN2) recombinant influenza vaccine in children.
    Beutner KR; Rizzone C; DeMello S; Ogra PL
    Dev Biol Stand; 1976; 33():162-70. PubMed ID: 782964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
    Brett IC; Johansson BE
    Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination.
    Muhamed G; Greenbaum E; Zakay-Rones Z
    Isr Med Assoc J; 2006 Mar; 8(3):155-8. PubMed ID: 16599048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses.
    Li S; Liu C; Klimov A; Subbarao K; Perdue ML; Mo D; Ji Y; Woods L; Hietala S; Bryant M
    J Infect Dis; 1999 May; 179(5):1132-8. PubMed ID: 10191214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Correlation of antineuraminidase antibodies and antihemagglutinins in influenza and following administration of live influenza vaccine].
    Nekliudova LI; Fedorova IuB; Orlova NG
    Vopr Virusol; 1974; (2):173-6. PubMed ID: 4446555
    [No Abstract]   [Full Text] [Related]  

  • 13. Antibody response to influenza vaccine in coronary artery disease: a substudy of the FLUCAD study.
    Brydak LB; Romanowska M; Nowak I; Ciszewski A; Bilińska ZT
    Med Sci Monit; 2009 Jul; 15(7):PH85-91. PubMed ID: 19564837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody responses to inactivated influenza vaccines and partial protective effect of anti-neuraminidase antibody against epidemics of A(H3N2) and A(H1N1) influenza.
    Maeda A; Oishi I; Minekawa Y; Kunita N; Funahashi S; Yagura H
    Biken J; 1979 Sep; 22(3):91-8. PubMed ID: 533537
    [No Abstract]   [Full Text] [Related]  

  • 15. Generation and evaluation of an H9N1 influenza vaccine derived by reverse genetics that allows utilization of a DIVA strategy for control of H9N2 avian influenza.
    Wu R; Chen Q; Zheng L; Chen J; Sui Z; Guan Y; Chen Z
    Arch Virol; 2009; 154(8):1203-10. PubMed ID: 19543688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of antineuraminidase antibodies in protection against influenza].
    Aymard M; Gerentes L; Kessler N
    Bull Acad Natl Med; 1998; 182(8):1723-36; discussion 1736-7. PubMed ID: 10188318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 May; 58(19):521-4. PubMed ID: 19478718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.
    Tamura S; Tanimoto T; Kurata T
    Jpn J Infect Dis; 2005 Aug; 58(4):195-207. PubMed ID: 16116250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Characteristics of immunity in influenza].
    Zilişteanu E; Creţescu L; Maţepiuc
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1975; 20(3):137-46. PubMed ID: 128102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.